The cornerstone of treatment is systemic therapy: hormone therapy in HR-positive subtypes (especially in combination with CDK4/6 inhibitors), targeted therapy for HER2-positive tumors, and chemotherapy for triple-negative breast cancer. This evidence concerns the gene CDK4 and triple-negative breast carcinoma.